Natco Pharma shares slip over 12% on USFDA observations, should you buy?

By: |
New Delhi | Updated: March 28, 2016 4:33 PM

Natco Pharma shares tumbled over 12 per cent on Monday after the company on Sunday said it has received “minor” observations by US Food & Drug Administration

natco pharma, bse sensex, usfdaNatco Pharma shares tumbled over 12 per cent on Monday after the company on Sunday said it has received “minor” observations by US Food & Drug Administration (USFDA) (Photo: PTI)

Natco Pharma shares tumbled over 12 per cent on Monday after the company on Sunday said it has received “minor” observations by US Food & Drug Administration (USFDA) following recent inspections at its two facilities and they will not have an adverse impact on its current or future products.

The share price of Natco Pharma settled 12.61 per cent down at Rs 409.30.

In a BSE filing, Natco Pharma said, “An inspection was conducted by the United States Food & Drug Administration (USFDA) in two of its manufacturing facilities recently the Active Pharmaceutical Ingredients (API) manufacturing facility at Manali, near Chennai, and the Pharmaceutical Formulations facility at Kothur, near Hyderabad, during early February and March, 2016, respectively.”

The company has received 483 observations for both facilities and believes them to be of minor in
nature. “The company has already sent response and compliance report for these observations and believes that there would be no adverse impact to its current or future pipeline products coming from these facilities,” Natco Pharma said in a BSE filing.

Religare Securities in a research note said, “We expect the stock to remain under pressure in the near term but retain our estimates until further clarity emerges. We have a ‘Buy’ rating on the stock with a target price of Rs 580.”

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Ipca Laboratories Rating ‘Buy’; Growth levers are intact for the company
2Bharat Petroleum Rating ‘Buy’; No divestment premium in current price
3Low credit growth, FII outflow weigh on financial stocks